risperidone has been researched along with Chemical Dependence in 34 studies
Risperidone: A selective blocker of DOPAMINE D2 RECEPTORS and SEROTONIN 5-HT2 RECEPTORS that acts as an atypical antipsychotic agent. It has been shown to improve both positive and negative symptoms in the treatment of SCHIZOPHRENIA.
risperidone : A member of the class of pyridopyrimidines that is 2-methyl-6,7,8,9-tetrahydropyrido[1,2-a]pyrimidin-4-one carrying an additional 2-[4-(6-fluoro-1,2-benzoxazol-3-yl)piperidin-1-yl]ethyl group at position 2.
| Excerpt | Relevance | Reference |
|---|---|---|
| "A long-term randomized trial of unstable patients with schizophrenia found no benefit of long-acting injectable (LAI) risperidone over oral treatment in preventing or delaying time to psychiatric hospitalizations or on clinical outcomes." | 9.19 | Differences in treatment effect among clinical subgroups in a randomized clinical trial of long-acting injectable risperidone and oral antipsychotics in unstable chronic schizophrenia. ( Krystal, JH; Leatherman, SM; Lew, RA; Liang, MH; Rosenheck, RA; Thwin, SS; Valley, D, 2014) |
| "The purpose of this study is to compare the efficacy of olanzapine and risperidone for the acute treatment of first-episode schizophrenia patients with cannabis use disorders." | 9.15 | Olanzapine vs. risperidone in patients with first-episode schizophrenia and a lifetime history of cannabis use disorders: 16-week clinical and substance use outcomes. ( Kane, J; McCormack, J; Miller, R; Napolitano, B; Robinson, DG; Sevy, S; Sunday, S, 2011) |
| "This study aimed to compare the efficacy of long-acting risperidone and zuclopenthixol in subjects with schizophrenia and substance abuse." | 9.12 | Long-acting injectable risperidone compared with zuclopenthixol in the treatment of schizophrenia with substance abuse comorbidity. ( Alamo, C; Jiménez-Arriero, MA; López-Muñoz, F; Martínez, I; Ponce, G; Rubio, G, 2006) |
| "A long-term randomized trial of unstable patients with schizophrenia found no benefit of long-acting injectable (LAI) risperidone over oral treatment in preventing or delaying time to psychiatric hospitalizations or on clinical outcomes." | 5.19 | Differences in treatment effect among clinical subgroups in a randomized clinical trial of long-acting injectable risperidone and oral antipsychotics in unstable chronic schizophrenia. ( Krystal, JH; Leatherman, SM; Lew, RA; Liang, MH; Rosenheck, RA; Thwin, SS; Valley, D, 2014) |
| "The purpose of this study is to compare the efficacy of olanzapine and risperidone for the acute treatment of first-episode schizophrenia patients with cannabis use disorders." | 5.15 | Olanzapine vs. risperidone in patients with first-episode schizophrenia and a lifetime history of cannabis use disorders: 16-week clinical and substance use outcomes. ( Kane, J; McCormack, J; Miller, R; Napolitano, B; Robinson, DG; Sevy, S; Sunday, S, 2011) |
| "Among patients with chronic schizophrenia who avoid use of illicit drugs, olanzapine was more effective than other antipsychotics as reflected by longer time to all-cause discontinuation, but illicit substance abuse attenuated this advantage, reinforcing the need for concurrent substance abuse treatment." | 5.13 | The effectiveness of antipsychotic medications in patients who use or avoid illicit substances: results from the CATIE study. ( Canive, JM; Davis, SM; Hsiao, JK; Khan, A; Lieberman, JA; McEvoy, JP; McGee, M; Miller, DD; Reimherr, F; Stroup, TS; Swanson, JW; Swartz, MS; Wagner, HR, 2008) |
| "This study aimed to compare the efficacy of long-acting risperidone and zuclopenthixol in subjects with schizophrenia and substance abuse." | 5.12 | Long-acting injectable risperidone compared with zuclopenthixol in the treatment of schizophrenia with substance abuse comorbidity. ( Alamo, C; Jiménez-Arriero, MA; López-Muñoz, F; Martínez, I; Ponce, G; Rubio, G, 2006) |
| "This 12-month, prospective, observational study investigated factors associated with symptomatic remission (total YMRS score < or =12) and full clinical recovery (sustained reduction in CGI-BP-S overall score) in bipolar disorder during treatment with atypical antipsychotics (predominantly olanzapine, risperidone and quetiapine; alone or in combination with a psychotropic such as lithium or valproate) in actual clinical practice." | 3.76 | Twelve-month prospective, multinational, observational study of factors associated with recovery from mania in bipolar disorder in patients treated with atypical antipsychotics. ( Badr, MG; D'yachkova, Y; Dikeos, D; Fábián, Z; Harrison, G; Hudiţă, C; Okasha, T; Pesek, MB; Tapia-Paniagua, G; Treuer, T; Yang, F, 2010) |
| " Patients aged 2 18 years who received an initial prescription for olanzapine, risperidone, quetiapine or amisulpride between April 1 and September 30, 2003; and had an ICD-10-coded diagnosis of schizophrenia were included." | 3.74 | Atypical antipsychotic therapy for treatment of schizophrenia in Hong Kong Chinese patients--a cost analysis. ( Hui, HY; Law, WL; You, JH; Young, WM, 2007) |
| "Risperidone was associated with more detrimental subjective experiences compared with paliperidone ER and placebo (p < ." | 2.77 | Different safety profiles of risperidone and paliperidone extended-release: a double-blind, placebo-controlled trial with healthy volunteers. ( Chung, YC; Kim, MG; Oh, KY; Park, MS; Park, TW; Yang, JC; Yoon, KS, 2012) |
| " Based on recent criteria for pediatric populations, patients were considered "at risk for adverse health outcome" if they met at least 1 of the following criteria: (1) > or = 85th BMI percentile plus presence of 1 or more negative weight-related clinical outcomes, or (2) > or = 95th BMI percentile." | 2.73 | Metabolic and hormonal side effects in children and adolescents treated with second-generation antipsychotics. ( Arango, C; Cifuentes, A; Fraguas, D; Giráldez, M; Laita, P; Merchán-Naranjo, J; Moreno, D; Parellada, M; Ruiz-Sancho, A, 2008) |
| "Risperidone was compared to clozapine, olanzapine, perphenazine, quetiapine and ziprasidone." | 2.58 | Risperidone versus other antipsychotics for people with severe mental illness and co-occurring substance misuse. ( Siegfried, N; Stein, DJ; Temmingh, HS; Williams, T, 2018) |
| "In patients with a psychotic disorder, substance abuse is a major problem." | 2.45 | Differences in efficacy on substance abuse between risperidone and clozapine supports the importance of differential modulation of dopaminergic neurotransmission. ( de Haan, L; Machielsen, MW, 2009) |
| "Little is known about the influence of substance use on side effects." | 1.62 | The Influence of Substance Use on Side Effects of Olanzapine, Quetiapine, Risperidone, and Ziprasidone in Psychosis. ( Alisauskiene, R; Gjestad, R; Johnsen, E; Jørgensen, HA; Kroken, RA; Løberg, EM, 2021) |
| "Risperidone LAT was typically used with recommended age and diagnostic groups." | 1.37 | Risperidone long-acting therapy prescribing patterns and their impact on early discontinuation of treatment in a large Medicaid population. ( Becker, MA; Boaz, TL; Constantine, RJ; Howe, AM; Robst, J, 2011) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 5 (14.71) | 18.2507 |
| 2000's | 15 (44.12) | 29.6817 |
| 2010's | 10 (29.41) | 24.3611 |
| 2020's | 4 (11.76) | 2.80 |
| Authors | Studies |
|---|---|
| Thurstone, C | 1 |
| Loh, R | 1 |
| Foreman, K | 1 |
| Thurstone, CA | 1 |
| Wolf, C | 1 |
| Drevin, G | 1 |
| Picard, N | 1 |
| Jousset, N | 1 |
| Briet, M | 1 |
| Abbara, C | 1 |
| Aras, N | 1 |
| Alisauskiene, R | 1 |
| Johnsen, E | 1 |
| Gjestad, R | 1 |
| Kroken, RA | 1 |
| Jørgensen, HA | 1 |
| Løberg, EM | 1 |
| Temmingh, HS | 1 |
| Williams, T | 1 |
| Siegfried, N | 1 |
| Stein, DJ | 1 |
| Leatherman, SM | 1 |
| Liang, MH | 1 |
| Krystal, JH | 1 |
| Lew, RA | 1 |
| Valley, D | 1 |
| Thwin, SS | 1 |
| Rosenheck, RA | 2 |
| Mohamed, S | 1 |
| Lin, H | 1 |
| Swartz, M | 1 |
| McEvoy, J | 1 |
| Stroup, S | 1 |
| Saglam, O | 1 |
| Bahsi, R | 1 |
| Akkoca, Y | 1 |
| Filik, L | 1 |
| Fraguas, D | 1 |
| Merchán-Naranjo, J | 1 |
| Laita, P | 1 |
| Parellada, M | 1 |
| Moreno, D | 1 |
| Ruiz-Sancho, A | 1 |
| Cifuentes, A | 1 |
| Giráldez, M | 1 |
| Arango, C | 1 |
| Khantzian, EJ | 1 |
| Albanese, MJ | 2 |
| Rothermel, B | 1 |
| Poustka, L | 1 |
| Banaschewski, T | 1 |
| Becker, K | 1 |
| Dikeos, D | 1 |
| Badr, MG | 1 |
| Yang, F | 1 |
| Pesek, MB | 1 |
| Fábián, Z | 1 |
| Tapia-Paniagua, G | 1 |
| Hudiţă, C | 1 |
| Okasha, T | 1 |
| D'yachkova, Y | 1 |
| Harrison, G | 1 |
| Treuer, T | 1 |
| Parikh, SV | 1 |
| LeBlanc, SR | 1 |
| Ovanessian, MM | 1 |
| Machielsen, MW | 1 |
| de Haan, L | 1 |
| Boaz, TL | 1 |
| Constantine, RJ | 1 |
| Robst, J | 1 |
| Becker, MA | 1 |
| Howe, AM | 1 |
| Sevy, S | 1 |
| Robinson, DG | 1 |
| Sunday, S | 1 |
| Napolitano, B | 1 |
| Miller, R | 1 |
| McCormack, J | 1 |
| Kane, J | 1 |
| Yoon, KS | 1 |
| Park, TW | 1 |
| Yang, JC | 1 |
| Kim, MG | 1 |
| Oh, KY | 1 |
| Park, MS | 1 |
| Chung, YC | 1 |
| Green, AI | 1 |
| Burgess, ES | 1 |
| Dawson, R | 1 |
| Zimmet, SV | 1 |
| Strous, RD | 1 |
| Gasquet, I | 1 |
| Haro, JM | 1 |
| Novick, D | 1 |
| Edgell, ET | 1 |
| Kennedy, L | 1 |
| Lepine, JP | 1 |
| Lambert, M | 1 |
| Conus, P | 1 |
| Lubman, DI | 1 |
| Wade, D | 1 |
| Yuen, H | 1 |
| Moritz, S | 1 |
| Naber, D | 1 |
| McGorry, PD | 1 |
| Schimmelmann, BG | 1 |
| Rubio, G | 1 |
| Martínez, I | 1 |
| Ponce, G | 1 |
| Jiménez-Arriero, MA | 1 |
| López-Muñoz, F | 1 |
| Alamo, C | 1 |
| Bellack, AS | 1 |
| Brown, CH | 1 |
| Thomas-Lohrman, S | 1 |
| Smelson, DA | 2 |
| Tunis, SL | 1 |
| Nyhuis, AW | 1 |
| Faries, DE | 1 |
| Kinon, BJ | 1 |
| Ascher-Svanum, H | 1 |
| Law, WL | 1 |
| Hui, HY | 1 |
| Young, WM | 1 |
| You, JH | 1 |
| Swartz, MS | 1 |
| Wagner, HR | 1 |
| Swanson, JW | 1 |
| Stroup, TS | 1 |
| McEvoy, JP | 1 |
| Reimherr, F | 1 |
| Miller, DD | 1 |
| McGee, M | 1 |
| Khan, A | 1 |
| Canive, JM | 1 |
| Davis, SM | 1 |
| Hsiao, JK | 1 |
| Lieberman, JA | 1 |
| Bacher, NM | 1 |
| Kaup, BA | 1 |
| Roy, A | 1 |
| Roy, M | 1 |
| Misra, L | 1 |
| Kofoed, L | 2 |
| Iyo, M | 1 |
| Sekine, Y | 1 |
| Matsunaga, T | 1 |
| Tsukamoto, T | 1 |
| Takei, N | 1 |
| Mori, N | 1 |
| Misra, LK | 1 |
| Fuller, W | 1 |
| Solhkhah, R | 1 |
| Finkel, J | 1 |
| Hird, S | 1 |
| Gupta, N | 1 |
| Basu, D | 1 |
| Isbister, GK | 1 |
| Whyte, IM | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Risperidone Long-Acting for Alcohol and Schizophrenia Treatment (R-LAST)[NCT00130923] | Phase 4 | 95 participants (Actual) | Interventional | 2005-09-30 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
Frequency of drinking days is obtained each week retrospectively as the number of drinking days during the prior week (assessed using the Timeline Followback). Mixed models are used to obtain estimates of efficacy from the partial data provided by each subject while adherent to assigned treatment (under the 'missing at random' assumption). The 'explanatory' estimands (target of the mixed model estimation) are defined in terms of population quantities that would have occurred had all subjects remained on assigned treatment throughout the study. The point estimate for each arm is reported under Number. (NCT00130923)
Timeframe: 6 months
| Intervention | drinking days per week (Number) |
|---|---|
| Risperidone Long Acting Injectable (LAI) | 2.84 |
| Oral Risperidone Aka Risperdal | 3.46 |
A rater assesses social, occupational and psychological functioning on a hypothetical continuum of mental health - illness (using Global Assessment of Functioning); scores range from 100 to 1, where higher values represent a better outcome. Mixed models are used to obtain estimates of efficacy from the partial data provided by each subject while adherent to assigned treatment (under the 'missing at random' assumption). The 'explanatory' estimands (target of the mixed model estimation) are defined in terms of population quantities that would have occurred had all subjects remained on assigned treatment throughout the study. The point estimate for each arm is reported under Number. (NCT00130923)
Timeframe: 6 months
| Intervention | ordinal severity of impairment (Number) |
|---|---|
| Risperidone Long Acting Injectable (LAI) | 50.8 |
| Oral Risperidone Aka Risperdal | 49.9 |
A rater assesses positive and negative symptoms of schizophrenia using a 30-item scale (Positive and Negative Symptom Score) Scores range from 30 to 210, where higher values represent a worse outcome. Mixed models are used to obtain estimates of efficacy from the partial data provided by each subject while adherent to assigned treatment (under the 'missing at random' assumption). The 'explanatory' estimands (target of the mixed model estimation) are defined in terms of population quantities that would have occurred had all subjects remained on assigned treatment throughout the study. The point estimate for each arm is reported under Number. (NCT00130923)
Timeframe: 6 months
| Intervention | ordinal severity of symptoms (Number) |
|---|---|
| Risperidone Long Acting Injectable (LAI) | 78.2 |
| Oral Risperidone Aka Risperdal | 75.5 |
A rater assesses the severity of illness and global impression using a scale from 1 to 7 (Clinical Global Impression), where higher values represent a worse outcome. Mixed models are used to obtain estimates of efficacy from the partial data provided by each subject while adherent to assigned treatment (under the 'missing at random' assumption). The 'explanatory' estimands (target of the mixed model estimation) are defined in terms of population quantities that would have occurred had all subjects remained on assigned treatment throughout the study. The point estimate for each arm is reported under Number. (NCT00130923)
Timeframe: 6 months
| Intervention | ordinal unit of severity (Number) |
|---|---|
| Risperidone Long Acting Injectable (LAI) | 4.02 |
| Oral Risperidone Aka Risperal | 3.96 |
Frequency of heavy drinking days is obtained each week retrospectively as the number of heavy drinking days during the prior week (assessed by the Timeline Followback Scale). A heavy drinking day is defined as 4 or more drinks per day for a female and 5 or more drinks per day for a male. Mixed models are used to obtain estimates of efficacy from the partial data provided by each subject while adherent to assigned treatment (under the 'missing at random' assumption). The 'explanatory' estimands (target of the mixed model estimation) are defined in terms of population quantities that would have occurred had all subjects remained on assigned treatment throughout the study. The point estimate for each arm is reported under Number. (NCT00130923)
Timeframe: 6 months
| Intervention | heavy drinking days per week (Number) |
|---|---|
| Risperidone Long Acting Injectable (LAI) | -.11 |
| Oral Risperidone Aka Risperal | .68 |
Number of participants with medication adherence (defined as taking medication at least 75% of the days in the treatment period). (NCT00130923)
Timeframe: 6 months
| Intervention | Participants (Count of Participants) |
|---|---|
| Risperidone Long Acting Injectable (LAI) | 43 |
| Oral Risperidone Aka Risperdal | 28 |
2 reviews available for risperidone and Chemical Dependence
| Article | Year |
|---|---|
Risperidone versus other antipsychotics for people with severe mental illness and co-occurring substance misuse.
Topics: Antipsychotic Agents; Benzodiazepines; Clozapine; Diagnosis, Dual (Psychiatry); Humans; Mental Disor | 2018 |
Differences in efficacy on substance abuse between risperidone and clozapine supports the importance of differential modulation of dopaminergic neurotransmission.
Topics: Antipsychotic Agents; Clozapine; Humans; Psychotic Disorders; Receptors, Dopamine D1; Receptors, Dop | 2009 |
9 trials available for risperidone and Chemical Dependence
| Article | Year |
|---|---|
Differences in treatment effect among clinical subgroups in a randomized clinical trial of long-acting injectable risperidone and oral antipsychotics in unstable chronic schizophrenia.
Topics: Administration, Oral; Adult; Aged; Antipsychotic Agents; Chronic Disease; Drug Administration Schedu | 2014 |
Randomized Trial of the Effect of Four Second-Generation Antipsychotics and One First-Generation Antipsychotic on Cigarette Smoking, Alcohol, and Drug Use in Chronic Schizophrenia.
Topics: Adolescent; Adult; Aged; Alcoholism; Antipsychotic Agents; Benzodiazepines; Chronic Disease; Comorbi | 2015 |
Metabolic and hormonal side effects in children and adolescents treated with second-generation antipsychotics.
Topics: Adolescent; Benzodiazepines; Blood Glucose; Body Mass Index; Child; Diagnostic and Statistical Manua | 2008 |
Olanzapine vs. risperidone in patients with first-episode schizophrenia and a lifetime history of cannabis use disorders: 16-week clinical and substance use outcomes.
Topics: Adolescent; Adult; Antipsychotic Agents; Benzodiazepines; Body Weight; Female; Humans; Longitudinal | 2011 |
Different safety profiles of risperidone and paliperidone extended-release: a double-blind, placebo-controlled trial with healthy volunteers.
Topics: Adult; Analysis of Variance; Antipsychotic Agents; Chi-Square Distribution; Cognition; Double-Blind | 2012 |
Long-acting injectable risperidone compared with zuclopenthixol in the treatment of schizophrenia with substance abuse comorbidity.
Topics: Adolescent; Adult; Aged; Antipsychotic Agents; Clopenthixol; Comorbidity; Delayed-Action Preparation | 2006 |
Antipsychotic treatment discontinuation among individuals with schizophrenia and co-occurring substance use.
Topics: Antipsychotic Agents; Benzodiazepines; Humans; Olanzapine; Patient Dropouts; Risperidone; Schizophre | 2006 |
The effectiveness of antipsychotic medications in patients who use or avoid illicit substances: results from the CATIE study.
Topics: Adult; Antipsychotic Agents; Benzodiazepines; Chronic Disease; Comorbidity; Dibenzothiazepines; Doub | 2008 |
Safety and efficacy of risperidone in substance abusers with psychosis.
Topics: Adult; Antipsychotic Agents; Clozapine; Drug Therapy, Combination; Female; Humans; Male; Middle Aged | 2001 |
23 other studies available for risperidone and Chemical Dependence
| Article | Year |
|---|---|
Program Evaluation to Aid Choice of Aripiprazole or Risperidone for Hospitalized Adolescents with Cannabis Use Disorder and Psychosis.
Topics: Adolescent; Adolescent, Hospitalized; Antipsychotic Agents; Aripiprazole; Humans; Marijuana Abuse; P | 2023 |
Pitfalls and challenges associated with phenoconversion in forensic toxcicology.
Topics: Adult; Cytochrome P-450 CYP2C19; Cytochrome P-450 CYP2D6; Forensic Toxicology; Heterozygote; Humans; | 2021 |
A Case of Self-Cannibalism: An Extremely Rare Type of Self-Mutilation With Multiple Risk Factors.
Topics: Adult; Antipsychotic Agents; Antisocial Personality Disorder; Cannibalism; Electroconvulsive Therapy | 2021 |
The Influence of Substance Use on Side Effects of Olanzapine, Quetiapine, Risperidone, and Ziprasidone in Psychosis.
Topics: Adult; Benzodiazepines; Female; Humans; Male; Olanzapine; Piperazines; Psychotic Disorders; Quetiapi | 2021 |
Risperidone-induced hepatotoxicity in a patient addicted to synthetic cannabinoid.
Topics: Adult; Antipsychotic Agents; Cannabinoids; Chemical and Drug Induced Liver Injury; Drug Substitution | 2016 |
Self-medication, bipolar disorders, and stimulant dependence.
Topics: Affect; Antipsychotic Agents; Bipolar Disorder; Central Nervous System Stimulants; Comorbidity; Dibe | 2009 |
[Bipolar disorders as co-morbidity in childhood and adolescence--underdiagnosed or overinterpreted? Therapy of a 14-year-old boy with hyperkinetic conduct disorder and hypomania].
Topics: Adolescent; Aggression; Antipsychotic Agents; Attention Deficit and Disruptive Behavior Disorders; A | 2010 |
Twelve-month prospective, multinational, observational study of factors associated with recovery from mania in bipolar disorder in patients treated with atypical antipsychotics.
Topics: Adult; Antipsychotic Agents; Benzodiazepines; Bipolar Disorder; Comorbidity; Diagnostic and Statisti | 2010 |
Advancing bipolar disorder: key lessons from the Systematic Treatment Enhancement Program for Bipolar Disorder (STEP-BD).
Topics: Anticonvulsants; Antidepressive Agents, Second-Generation; Antipsychotic Agents; Anxiety Disorders; | 2010 |
Risperidone long-acting therapy prescribing patterns and their impact on early discontinuation of treatment in a large Medicaid population.
Topics: Administration, Oral; Adolescent; Adult; Aged; Antipsychotic Agents; Comorbidity; Delayed-Action Pre | 2011 |
Alcohol and cannabis use in schizophrenia: effects of clozapine vs. risperidone.
Topics: Adult; Aged; Alcohols; Antipsychotic Agents; Cannabis; Clozapine; Female; Humans; Male; Middle Aged; | 2003 |
Pharmacological treatment and other predictors of treatment outcomes in previously untreated patients with schizophrenia: results from the European Schizophrenia Outpatient Health Outcomes (SOHO) study.
Topics: Administration, Oral; Adult; Antipsychotic Agents; Benzodiazepines; Cohort Studies; Demography; Depr | 2005 |
The impact of substance use disorders on clinical outcome in 643 patients with first-episode psychosis.
Topics: Adult; Antipsychotic Agents; Australia; Benzodiazepines; Cohort Studies; Disease Progression; Female | 2005 |
Psychometric characteristics of role-play assessments of social skill in schizophrenia.
Topics: Adult; Antipsychotic Agents; Clozapine; Comorbidity; Crime Victims; Diabetes Mellitus, Type 2; Femal | 2006 |
Atypical antipsychotic therapy for treatment of schizophrenia in Hong Kong Chinese patients--a cost analysis.
Topics: Adult; Amisulpride; Antipsychotic Agents; Benzodiazepines; China; Cost of Illness; Cost-Benefit Anal | 2007 |
Combining risperidone with standard neuroleptics for refractory schizophrenic patients.
Topics: Antipsychotic Agents; Diagnosis, Dual (Psychiatry); Drug Therapy, Combination; Humans; Risperidone; | 1996 |
Risperidone and neuropsychological test performance in cocaine-withdrawn patients.
Topics: Adult; Antipsychotic Agents; Cocaine; Humans; Male; Neuropsychological Tests; Risperidone; Substance | 1997 |
Risperidone treatment of methamphetamine psychosis.
Topics: Drug Administration Schedule; Humans; Male; Methamphetamine; Middle Aged; Psychoses, Substance-Induc | 1997 |
Methamphetamine-associated obsessional symptoms and effective risperidone treatment: a case report.
Topics: Adult; Dopamine Antagonists; Humans; Male; Methamphetamine; Obsessive-Compulsive Disorder; Psychoses | 1999 |
Treatment of inhalant abuse with risperidone.
Topics: Administration, Inhalation; Adult; Gasoline; Humans; Male; Petroleum; Psychoses, Substance-Induced; | 1999 |
Possible risperidone-induced visual hallucinations.
Topics: Adolescent; Antimanic Agents; Antipsychotic Agents; Benzodiazepines; Bipolar Disorder; Diagnosis, Du | 2000 |
Does risperidone reduce concomitant substance abuse in cases of schizophrenia?
Topics: Adult; Codeine; Comorbidity; Diagnosis, Dual (Psychiatry); Ephedrine; Humans; Male; Risperidone; Sch | 2001 |
Atypical presentation of risperidone toxicity.
Topics: Adult; Antipsychotic Agents; Diagnosis, Differential; Drug Overdose; Female; Humans; Male; Miosis; R | 2002 |